Randomized Phase II Study Comparing Mitomycin, Cisplatin Plus Doxifluridine with Cisplatin Plus Doxifluridine in Advanced Unresectable Gastric Cancer

Abstract

Various chemotherapies have been used to treat inoperable gastric cancer. Most combination therapies include cisplatin (CDDP) and fluoropyrimidine (5-FUs), which are thought of as key drugs. In the present study, we randomly compared mitomycin (MMC) and CDDP plus doxifluridine (5’-DFUR), which is an oral 5-FU and an intermediate metabolite of capecitabine (Xeloda), with CDDP plus 5’-DFUR in advanced unresectable gastric cancer. Regimen A was CDDP (70 mg/m², by 2-hour intravenous drip infusion on day 1), MMC (7 mg/m², injected intravenously on day 2), and oral 5’-DFUR (1200 mg/m², on days 4 to 7, 11 to 14, 18 to 21 and 25 to 28; 3 days rest and 4 days administration). Regimen B was identical to regimen A without MMC. Results: The response rate was 25.0% (8/32 patients) in Regimen A, 17.2% (5/29) in Regimen B (p=0.541). The median survival time was 241 days in Regimen A and 179 days in Regimen B (p=0.498). In Regimen A, although no significant difference was observed, end points such as response rate and survival improved. Thus, we concluded that a randomized controlled phase III study with more subjects should be conducted.